WO2006122327A2 - Milk fat globule epidermal growth factor-factor viii and sepsis - Google Patents
Milk fat globule epidermal growth factor-factor viii and sepsis Download PDFInfo
- Publication number
- WO2006122327A2 WO2006122327A2 PCT/US2006/018774 US2006018774W WO2006122327A2 WO 2006122327 A2 WO2006122327 A2 WO 2006122327A2 US 2006018774 W US2006018774 W US 2006018774W WO 2006122327 A2 WO2006122327 A2 WO 2006122327A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mfg
- sepsis
- mammal
- treating
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention generally relates to treatment of sepsis. More specifically, the invention is directed to the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) to treat sepsis.
- MFG-E8 milk fat globule epidermal growth factor-factor VIII
- Activated protein C is the only FDA-approved specific treatment for sepsis, but its use is limited to non-surgical adult patients with severe sepsis. APC cannot be used in trauma victims and surgical patients who develop sepsis, due to its adverse effects on coagulation. Thus, there is a great need for an effective novel therapy for sepsis, especially surgical sepsis. The market potential for sepsis treatment is estimated at $10-25 billion annually in the United States alone.
- the present invention further addresses the role of MFG-E8 in sepsis and inflammation.
- the inventor has discovered that treating a mammal with milk fat globule epidermal growth factor-factor VIII (MFG-E8) can prevent or reduce physiologic effects of sepsis, including inflammation.
- the invention is directed to methods of treating a mammal undergoing sepsis.
- the methods comprise treating the mammal with a milk fat globule epidermal growth factor-factor VIII (MFG-E8) such that a physiologic effect of the sepsis is prevented or reduced.
- the invention is directed to methods of treating a mammal at risk for sepsis.
- the methods comprise treating the mammal with a milk fat globule epidermal growth factor-factor VIII (MFG-E8) sufficient to prevent or reduce a physiologic effect of the sepsis.
- the present invention is directed to methods of preventing or treating a physiologic effect of sepsis in a mammal.
- the methods comprise treating the mammal with a milk fat globule epidermal growth factor-factor VIII (MFG-E8) such that a physiologic effect of the sepsis is prevented or reduced.
- the invention is directed to the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal.
- MFG-E8 milk fat globule epidermal growth factor-factor VIII
- the invention is also directed to the use of milk fat globule epidermal growth factor- factor VIII (MFG-E8) for the treatment of a mammal having sepsis or at risk for sepsis.
- MFG-E8 milk fat globule epidermal growth factor- factor VIII
- FIG. 1 shows the protein expression of MFG-E8 in RAW 264.7 macrophages (RM ⁇ ) ⁇ LPS, where the values are LPS added, in ng/ml.
- FIG. 2 is a graph of experimental results showing increased survival of rats undergoing sepsis when treated with MFG-E8.
- FIG. 3 is a graph of experimental results showing that plasma MFG-E8 levels decrease 20 hours after CLP.
- FIG. 4 is photographs of western blots showing that MFG-E8 is only expressed in immature dendritic cells (6-8 day culture).
- FIG. 5 is a graph of experimental results showing that peritoneal M ⁇ isolated from septic rats treated with MFG-E8+ exosomes increases the phagocytosis index of those cells.
- FIG. 6 is a graph of experimental results showing that administration of MFG-E8+ exosomes to rats 5 and 20 hours after CLP (i.e., post-treatment) increases survival.
- FIG. 7 is a graph of experimental results showing that anti-MFG-E8 antibodies prevents downregulation of IL-6 induced by MFG-E8.
- FIG. 8 is a graph of experimental results showing that rMFG-E8 increases the phagocytosis index (Panel A) and attenuates IL-6 levels (Panel B) after CLP.
- FIG. 9 is a graph of experimental results showing that rMFG-E8 increases peritoneal M ⁇ phagocytosis index in vitro.
- FIG. 10 is a graph of experimental results showing that rMFG-E8 decreases peritoneal M ⁇ TNF- ⁇ release after 3h incubation in low-dose LPS and apoptotic thymocytes.
- the present invention is based in part on the discovery that treating a mammal with a milk fat globule epidermal growth factor-factor VIII (MFG-E8) can prevent or reduce physiologic effects of sepsis and inflammation.
- MFG-E8 milk fat globule epidermal growth factor-factor VIII
- the present invention is directed to methods of treating a mammal undergoing sepsis.
- the methods comprise treating the mammal with a milk fat globule epidermal growth factor-factor VIII (MFG-E8) such that a physiologic effect of the sepsis is prevented or reduced.
- MFG-E8 has an amino acid sequence at least 80%, more preferably at least 90%, even more preferably 95%, still more preferably, at least 99% identical to SEQ ID NO: 1 or SEQ ID NO:2, which are the sequences of a human MFG-E8 and mouse MFG-E8, respectively.
- the MFG-E8 sequence is completely homologous to SEQ ID NO: 1.
- the MFG-E8 in these embodiments can be in purified form, e.g., as a protein purified from a natural source or as a transgenic protein expressed from a recombinant cell.
- the MFG-E8 can be in combination with other therapeutic agents and/or only partially purified (e.g., further comprising cellular components, such as in the form of MFG-E8- rich exosomes derived from bone marrow dendritic cells [see Examples] or from other mammalian cells, including cells transformed with transgenic MFG-E8).
- the exosomes are preferably from the same species as the treated mammal; more preferably, the exosomes are from the same individual.
- the MFG-E8 can have a wild-type sequence from any mammalian species, or can comprise mutations, provided the mutations do not eliminate the protein's activity to prevent or reduce a physiologic effect of the sepsis. Such mutants could be made without undue experimentation. The activity of those mutants can also be easily determined by known methods and the methods described herein.
- the MFG-E8 can also comprise peptidomimetics.
- an amino acid mimetic or peptidomimetic is a compound that is capable of mimicking a natural parent amino acid in a protein, in that the substitution of an amino acid with the peptidomimetic does not significantly affect the activities of interest of the protein, in this case, the therapeutic activity of exogenous MFG-E8 in phagocytosis, sepsis and inflammation.
- Proteins comprising peptidomimetics are generally poor substrates of proteases and are likely to be active in vivo for a longer period of time as compared to the natural proteins. In addition, they could be less antigenic and show an overall higher bioavailability.
- MFG-E8 preparations are preferably formulated in a pharmaceutical composition. These compositions can be formulated without undue experimentation for administration to a mammal, including humans, as appropriate for the particular application. Additionally, proper dosages of the compositions can be determined without undue experimentation using standard dose-response protocols.
- compositions designed for oral, lingual, sublingual, buccal and intrabuccal administration can be made without undue experimentation by means well known in the art, for example with an inert diluent or with an edible carrier.
- the compositions may be enclosed in gelatin capsules or compressed into tablets.
- the pharmaceutical compositions of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like.
- Tablets, pills, capsules, troches and the like may also contain binders, recipients, disintegrating agent, lubricants, sweetening agents, and flavoring agents.
- binders include microcrystalline cellulose, gum tragacanth or gelatin.
- excipients include starch or lactose.
- disintegrating agents include alginic acid, corn starch and the like.
- lubricants include magnesium stearate or potassium stearate.
- An example of a glidant is colloidal silicon dioxide.
- sweetening agents include sucrose, saccharin and the like.
- flavoring agents include peppermint, methyl salicylate, orange flavoring and the like. Materials used in preparing these various compositions should be pharmaceutically pure and nontoxic in the amounts used.
- compositions of the present invention can easily be administered parenterally such as for example, by intravenous, intramuscular, intrathecal or subcutaneous injection.
- Parenteral administration can be accomplished by incorporating the compositions of the present invention into a solution or suspension.
- solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents.
- Parenteral formulations may also include antibacterial agents such as for example, benzyl alcohol or methyl parabens, antioxidants such as for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA.
- Buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added.
- the parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
- Rectal administration includes administering the pharmaceutical compositions into the rectum or large intestine. This can be accomplished using suppositories or enemas.
- Suppository formulations can easily be made by methods known in the art. For example, suppository formulations can be prepared by heating glycerin to about 120° C, dissolving the composition in the glycerin, mixing the heated glycerin after which purified water may be added, and pouring the hot mixture into a suppository mold.
- Transdermal administration includes percutaneous absorption of the composition through the skin.
- Transdermal formulations include patches (such as the well-known nicotine patch), ointments, creams, gels, salves and the like.
- nasally administering or nasal administration includes administering the composition to the mucous membranes of the nasal passage or nasal cavity of the patient.
- pharmaceutical compositions for nasal administration of a composition include therapeutically effective amounts of the composition prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. Administration of the composition may also take place using a nasal tampon or nasal sponge.
- the methods of the present invention prevent or reduce any physiologic effect of sepsis, including shock (which in turn affects endothelial cell function, smooth muscle contractility, cardiac output, stroke volume, systemic oxygen delivery, lactic acidosis, hemoconcentration, total peripheral vascular resistance and/or regional blood perfusion), renal function, hepatic function, gut absorptive function, adrenal function, insulin responsiveness, altered cytokine (e.g., IL-10, TNF- ⁇ , IL-I ⁇ and/or EL-6) release, and physiological effects of altered cytokine release (e.g., inflammation).
- shock which in turn affects endothelial cell function, smooth muscle contractility, cardiac output, stroke volume, systemic oxygen delivery, lactic acidosis, hemoconcentration, total peripheral vascular resistance and/or regional blood perfusion
- renal function hepatic function
- gut absorptive function e.g., IL-10, TNF- ⁇ , IL-I ⁇ and/or EL-6
- the measured physiological effect of the sepsis is elevation of serum TNF- ⁇ or EL- 6 levels, or evaluation of thymocyte apoptosis, as in the Example. Determination of shock, or its direct effects (e.g., hemoconcentration, peripheral vascular resistance, etc.) is also easily measured and can be utilized.
- These methods can also comprise treating the mammal with a second treatment that can reduce a physiological effect of the sepsis.
- a second treatment that can reduce a physiological effect of the sepsis.
- Nonlimiting examples of such treatments include administration of adrenomedullin, adrenomedullin binding protein, activated protein C, or an 0C 2A - adrenergic antagonist.
- the latter treatment is described in U.S. Provisional Patent Application 60/680,999, entitled TREATMENT OF SEPSIS AND INFLAMMATION WITH ALPHA 2A ADRENERGIC ANTAGONISTS, and filed simultaneously with the present application.
- the present invention is also directed to methods of treating a mammal at risk for sepsis.
- the methods comprise treating the mammal with a milk fat globule epidermal growth factor- factor VIII (MFG-E8) sufficient to prevent or reduce a physiologic effect of the sepsis.
- MFG-E8 has an amino acid sequence at least 90% identical to SEQ ID NO: 1 or SEQ ID NO:2, which are the sequences of a human MFG-E8 and mouse MFG-E8, respectively.
- the MFG-E8 in these embodiments can be in purified form or in combination with other therapeutic agents and/or only partially purified.
- the MFG-E8 can have a wild-type sequence from any mammalian species, or can comprise mutations, provided the mutations do not eliminate the protein's activity to prevent or reduce a physiologic effect of the sepsis.
- the MFG-E8 can also comprise peptidomimetics. Where the MFG-E8 is from MFG-E8-rich exosomes, the exosomes are preferably from the same species as the treated mammal; more preferably, the exosomes are from the same individual.
- the methods of the present invention prevent or reduce physiologic effects of sepsis, such as shock, elevation of serum TNF- ⁇ levels, elevation of serum IL-6 levels, and physiological effects of altered cytokine release (e.g., inflammation).
- physiologic effects that are easily measured are evaluated. Examples of these effects are elevation of serum TNF- ⁇ levels, elevation of serum ALT levels, elevation of serum AST levels, elevation of serum lactate, and elevation of serum creatinine.
- the measured physiological effect of the sepsis is elevation of serum TNF- ⁇ or IL-6 levels, or evaluation of thymocyte apoptosis, as in the Example.
- These methods can also comprise treating the mammal with a second treatment that can reduce a physiological effect of the sepsis.
- treatments include administration of adrenomedullin, adrenomedullin binding protein, activated protein C, or an ⁇ 2A -adrenergic antagonist.
- the invention is directed to methods of preventing or treating a physiologic effect of sepsis in a mammal.
- the methods comprise treating the mammal with a milk fat globule epidermal growth factor-factor VIII (MFG-E8) such that a physiologic effect of the sepsis is prevented or reduced.
- MFG-E8 milk fat globule epidermal growth factor-factor VIII
- the MFG-E8 has an amino acid sequence at least 90% identical to SEQ ID NO: 1 or SEQ ID NO:2, which are the sequences of a human MFG-E8 and mouse MFG-E8, respectively. These methods can be used with any mammal, including humans.
- the MFG-E8 in these embodiments can be in purified form or in combination with other therapeutic agents and/or only partially purified.
- the MFG-E8 can have a wild-type sequence from any mammalian species, or can comprise mutations, provided the mutations do not eliminate the protein's activity to prevent or reduce a physiologic effect of the sepsis.
- the MFG-E8 can also comprise peptidomimetics. Where the MFG-E8 is from MFG-E8-rich exosomes, the exosomes are preferably from the same species as the treated mammal; more preferably, the exosomes are from the same individual.
- the methods of the present invention prevent or reduce any physiologic effect of sepsis, including shock, elevation of serum TNF- ⁇ levels, elevation of serum IL-6 levels, and physiological effects of altered cytokine release (e.g., inflammation).
- physiologic effects that are easily measured are evaluated. Examples of these effects are elevation of serum TNF- ⁇ levels, elevation of serum ALT levels, elevation of serum AST levels, elevation of serum lactate, and elevation of serum creatinine.
- the measured physiological effect of the sepsis is elevation of serum TNF- ⁇ or IL-6 levels, or evaluation of thymocyte apoptosis, as in the Example.
- These methods can also comprise treating the mammal with a second treatment that can reduce a physiological effect of the sepsis.
- a second treatment that can reduce a physiological effect of the sepsis.
- treatments include administration of adrenomedullin, adrenomedullin binding protein, activated protein C, or an ⁇ 2A -adrenergic antagonist.
- the present invention is additionally directed to the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal.
- MFG-E8 has an amino acid sequence at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2, which are the sequences of a human MFG-E8 and mouse MFG-E8, respectively.
- the invention is also directed to the use of milk fat globule epidermal growth factor-factor VEH (MFG-E8) for the treatment of a mammal having sepsis or at risk for sepsis.
- MFG-E8 has an amino acid sequence at least 90% identical to SEQ ED NO:1 or SEQ ID NO:2, which are the sequences of a human MFG-E8 and mouse MFG- E8, respectively.
- Apoptotic cells can harm the host in sepsis, if not cleared by phagocytes. Phagocytosis of apoptotic cells depends on "eat me” signals expressed on dying cells, such as phosphatidylserine (PS). PS can be recognized by phagocytes via its receptors. For complete engulfment of apoptotic cells, binding of PS to integrin 0 ⁇ 3 , mediated by the bridging protein milk fat globule epidermal growth factor-factor VIII (MFG-E8), is needed.
- MFG-E8 bridging protein milk fat globule epidermal growth factor-factor VIII
- phagocytosis of apoptotic cells is impaired in inflammation generally, and more particularly in sepsis due to the decreased MFG-E8 and that adaptive transfer of bone marrow DC (BMDC)-derived exosomes rich in MFG-E8 is beneficial.
- BMDC bone marrow DC
- sepsis was induced in rats by cecal ligation and puncture (CLP).
- CLP cecal ligation and puncture
- MFG-E8 was assessed by Western blot in CLP rats and in RAW 264.7 macrophages (RM ⁇ ) stimulated with LPS at 20 h.
- Exosomes 1000 ⁇ g
- BMDCs BMDCs
- TC- A 0 apoptotic thymocytes
- Peritoneal M ⁇ were cultured with exosomes (24 h) and their ability to engulf TC-A 0 was determined in vitro (phagocytosis index [PI]: TC-AQ/M ⁇ ).
- PI phagocytosis index
- Our results indicate that MFG-E8 in spleen and liver decreased by 48% and 70% respectively at 20 h after sepsis (Table 1).
- MFG-E8 expression also decreased after in vitro stimulation of RM ⁇ with LPS (FIG. 1). Injection of exosomes to CLP rats led to reduced detection OfTC-A 0 and plasma cytokines as shown in Table 2.
- peritoneal M ⁇ from exosome-treated rats displayed a 3.6-fold increased activity to phagocytose TC-A 0 (PI: 0.84 ⁇ 0.13 vs. 0.23 ⁇ 0.04 in Vehicle, PO.05).
- exosomes 250 ⁇ g each
- vehicle PBS
- MFG-E8 significantly improved the survival rate (FIG. 2).
- BMDC-derived exosomes which are a rich source of MFG-E8, attenuate systemic inflammation and improve survival in sepsis, by enhancing clearance of apoptotic cells.
- the increased availability of MFG-E8, a factor indispensable for phagocytosis of apoptotic cells, is the underlying mechanism.
- MFP-E8 was evaluated in BMDCs over time. From days 4-16, BMDCs were cultured with exosome-free FBS. Culture medium was collected and gradually centrifuged to remove cells and bigger particles and vesicles, and then ultracentrifuged at 100,000 xg to obtain exosomes. The collected pellet was washed and reconstituted with PBS, the amount of protein was assessed and the emulsion was adjusted to a concentration of 1 mg/ml in PBS. The existence of MFG-E8 in the exosome fraction was verified by Western blot with a maximal content of this protein on day 6 of BMDC culture (FIG. 4). Thus, MFG-E8 is only expressed in immature dendritic cells. Exosomes collected on days 6-8 were used as MFG-E8-containing (MFG-E8+) exosomes and those collected on days 14-16 were used as non-MFG-E8-containing exosomes.
- MFG-E8+ exosomes increased the phagocytosis index by 174.7% and 85.2%, as compared to vehicle-treated CLP and sham animals, respectively (P ⁇ 0.05 by ANOVA).
- MFG-E8+ exosomes reduces apoptosis, downregulates cytokines, and improves phagocytosis in sepsis.
- non-MFG-E8 -containing exosomes did not demonstrate any anti-apoptotic, anti-inflammatory, and phagocytotic properties (data not shown), indicating MFG-E8 is responsible for the observed effects.
- MFG-E8+ exosomes were given intravenously at 5 and 2Oh after CLP (i.e., post- treatment).
- survival was markedly improved (FIG. 6).
- the survival advantage was not observed when non-MFG-E8-containing exosomes were given.
- Non-MFG-E8-containing exosome-treated septic rats had even a slightly worse outcome as compared to vehicle-treated septic animals (data not shown).
- the specificity of MFG-E8 on exosomes is confirmed by the blocking antibodies.
- BMDC-derived exosomes may contain several other proteins that could influence our findings.
- blocking antibodies were used to inhibit MFG-E8 on exosomes prior to injection into septic rats.
- Fab-fragments were used instead of complete antibodies to block MFG- E8. The result indicates that MFG-E8+ exosome-mediated decrease of apoptotic thymocytes and increase in phagocytosis in septic rats can be completely reversed by inhibiting MFG-E8 prior to the injection of exosomes.
- MFG-E8 commercial rMFG-E8 has not been developed until very recently.
- the results presented below indicate that rMFG-E8 is as effective as BMDC-derived MFG-E8+ exosomes.
- the mouse rMFG-E8 (R & D Systems, Minneapolis, MN) used in our study is >95% purity with a molecular weight of 67 kDa (identical to the naturally occurring mouse MFG-E8), and of at least 95% homology to rat MFG-E8.
- our initial test indicates that mouse rMFG-E8 is highly effective in the rat.
- rMFG ⁇ E8 significantly decreased TNF- ⁇ release from peritoneal M ⁇ after 3 h incubation in the presence of low-dose LPS (10 ng/ml) and apoptotic thymocytes (FIG. 10).
- LPS low-dose LPS
- apoptotic thymocytes FIG. 10
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/920,304 US9321822B2 (en) | 2005-05-13 | 2006-05-12 | Milk fat globule epidermal growth factor—factor VIII and sepsis |
AU2006243905A AU2006243905B2 (en) | 2005-05-13 | 2006-05-12 | Milk fat globule epidermal growth factor-factor VIII and sepsis |
CN2006800223836A CN101203234B (en) | 2005-05-13 | 2006-05-12 | Milk fat globule epidermal growth factor VIII and sepsis |
CA2608271A CA2608271C (en) | 2005-05-13 | 2006-05-12 | Milk fat globule epidermal growth factor-factor viii and sepsis |
EP06784414.2A EP1888096B1 (en) | 2005-05-13 | 2006-05-12 | Milk fat globule epidermal growth factor-factor viii and sepsis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68062805P | 2005-05-13 | 2005-05-13 | |
US60/680,628 | 2005-05-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006122327A2 true WO2006122327A2 (en) | 2006-11-16 |
WO2006122327A8 WO2006122327A8 (en) | 2007-05-24 |
WO2006122327A3 WO2006122327A3 (en) | 2007-12-13 |
Family
ID=37397353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/018774 WO2006122327A2 (en) | 2005-05-13 | 2006-05-12 | Milk fat globule epidermal growth factor-factor viii and sepsis |
Country Status (6)
Country | Link |
---|---|
US (1) | US9321822B2 (en) |
EP (1) | EP1888096B1 (en) |
CN (1) | CN101203234B (en) |
AU (1) | AU2006243905B2 (en) |
CA (1) | CA2608271C (en) |
WO (1) | WO2006122327A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2215264A1 (en) * | 2007-11-15 | 2010-08-11 | The Feinstein Institute for Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 |
WO2013077186A1 (en) * | 2011-11-21 | 2013-05-30 | 国立大学法人筑波大学 | Activity modulator, medicinal agent comprising same, use of cd300a gene-deficient mouse, and anti-cd300a antibody |
US9850309B2 (en) | 2012-11-07 | 2017-12-26 | University Of Tsukuba | Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell |
WO2021044362A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Therapeutic fusion proteins |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703693B2 (en) * | 2004-03-31 | 2014-04-22 | The Feinstein Institute For Medical Research | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment |
WO2005097172A2 (en) | 2004-03-31 | 2005-10-20 | North Shore-Long Island Jewish Research Institute | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment |
ES2736726T3 (en) * | 2006-03-09 | 2020-01-07 | Aethlon Medical Inc | Extracorporeal removal of microvesicular particles |
CN101705290B (en) * | 2009-11-17 | 2011-12-28 | 西北农林科技大学 | Single nucleotide polymorphism of SCD genes in dairy goat and detection method thereof |
CN101705288B (en) * | 2009-11-17 | 2011-12-28 | 西北农林科技大学 | Mononucleotide polymorphism of milk goat MFG-E8 genes and detection method thereof |
AU2012249539A1 (en) * | 2011-04-28 | 2013-11-14 | The Feinstein Institute For Medical Research | MFG-E8 and uses thereof |
US9669070B2 (en) | 2013-09-17 | 2017-06-06 | The Feinstein Institute For Medical Research | Treatment and prevention of radiation injury using MFG-E8 |
WO2016179417A2 (en) * | 2015-05-06 | 2016-11-10 | The University Of Utah Research Foundation | Exosome delivery of micrornas |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1004664A1 (en) | 1998-11-24 | 2000-05-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods using lactadherin or variants thereof |
WO2003103700A1 (en) | 2002-06-07 | 2003-12-18 | U.S. Department Of Veterans Affairs | Method and composition for inhibing or slowing blood coagulation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4662708B2 (en) * | 2001-08-17 | 2011-03-30 | エクソセラ・エルエルシー | Methods and compositions for targeting proteins to exosomes |
JP4160292B2 (en) * | 2001-11-20 | 2008-10-01 | 独立行政法人科学技術振興機構 | Promoter and inhibitor for removal of apoptotic cells in vivo |
AU2008321386B2 (en) | 2007-11-15 | 2014-10-23 | The Feinstein Institute For Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8 |
AU2012249539A1 (en) | 2011-04-28 | 2013-11-14 | The Feinstein Institute For Medical Research | MFG-E8 and uses thereof |
-
2006
- 2006-05-12 WO PCT/US2006/018774 patent/WO2006122327A2/en active Application Filing
- 2006-05-12 AU AU2006243905A patent/AU2006243905B2/en not_active Ceased
- 2006-05-12 EP EP06784414.2A patent/EP1888096B1/en active Active
- 2006-05-12 CA CA2608271A patent/CA2608271C/en active Active
- 2006-05-12 US US11/920,304 patent/US9321822B2/en not_active Expired - Fee Related
- 2006-05-12 CN CN2006800223836A patent/CN101203234B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1004664A1 (en) | 1998-11-24 | 2000-05-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods using lactadherin or variants thereof |
WO2003103700A1 (en) | 2002-06-07 | 2003-12-18 | U.S. Department Of Veterans Affairs | Method and composition for inhibing or slowing blood coagulation |
Non-Patent Citations (4)
Title |
---|
KIEBER-EMMONS ET AL., CURR. OPIN. BIOTECHNOL., vol. 8, 1997, pages 435 - 441 |
RIPKA ET AL., CURR. OPIN. CHEM. BIOL., vol. 2, 1998, pages 441 - 452 |
SANDERSON, MED. RES. REV., vol. 19, 1999, pages 179 - 197 |
See also references of EP1888096A4 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9018157B2 (en) | 2007-11-15 | 2015-04-28 | The Feinstein Institute For Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8 |
CN101910411A (en) * | 2007-11-15 | 2010-12-08 | 范斯坦医药研究院 | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8 |
EP2215264A4 (en) * | 2007-11-15 | 2011-03-23 | The Feinstein Inst Medical Res | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 |
EP2215264A1 (en) * | 2007-11-15 | 2010-08-11 | The Feinstein Institute for Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 |
AU2008321386B2 (en) * | 2007-11-15 | 2014-10-23 | The Feinstein Institute For Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8 |
CN101910411B (en) * | 2007-11-15 | 2015-04-29 | 范斯坦医药研究院 | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8 |
WO2013077186A1 (en) * | 2011-11-21 | 2013-05-30 | 国立大学法人筑波大学 | Activity modulator, medicinal agent comprising same, use of cd300a gene-deficient mouse, and anti-cd300a antibody |
JPWO2013077186A1 (en) * | 2011-11-21 | 2015-04-27 | 国立大学法人 筑波大学 | Activity regulator, pharmaceutical containing the same, use of CD300a gene-deficient mouse and anti-CD300a antibody |
US10519233B2 (en) | 2011-11-21 | 2019-12-31 | University Of Tsukuba | Activity modulator, medicinal agent comprising same, use of CD300A gene-deficient mouse, and anti-CD300A antibody |
US9850309B2 (en) | 2012-11-07 | 2017-12-26 | University Of Tsukuba | Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell |
WO2021044362A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Therapeutic fusion proteins |
WO2021044360A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Therapeutic fusion proteins |
WO2021044361A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Therapeutic fusion proteins |
Also Published As
Publication number | Publication date |
---|---|
CA2608271C (en) | 2016-01-19 |
CN101203234A (en) | 2008-06-18 |
AU2006243905A1 (en) | 2006-11-16 |
CA2608271A1 (en) | 2006-11-16 |
US9321822B2 (en) | 2016-04-26 |
WO2006122327A3 (en) | 2007-12-13 |
CN101203234B (en) | 2012-10-10 |
EP1888096B1 (en) | 2017-12-27 |
EP1888096A2 (en) | 2008-02-20 |
US20090297498A1 (en) | 2009-12-03 |
WO2006122327A8 (en) | 2007-05-24 |
AU2006243905B2 (en) | 2011-09-01 |
EP1888096A4 (en) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9321822B2 (en) | Milk fat globule epidermal growth factor—factor VIII and sepsis | |
US7879318B2 (en) | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand | |
US20140121163A1 (en) | Mfg-e8 and uses thereof | |
Wiersinga | Hypothyroidism and myxedema coma | |
RU2592983C2 (en) | Combined therapy including vemurafenib and interferon, for use in treating cancer | |
JP2011506436A (en) | Method of treatment of melanoma with alpha thymosin peptide combined with antibody against cytotoxic T lymphocyte antigen 4 (CTLA4) | |
EP3881856A1 (en) | Pharmaceutical composition for treating aplastic anemia | |
US9101593B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
Porten et al. | Candidiasis endocrinopathy syndrome | |
US8703693B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
US20070004625A1 (en) | Use of complement inhibitory proteins to treat spinal cord injury | |
JP2007008876A (en) | Use of complement inhibitory protein for treating spinal cord injury | |
Arnhold et al. | Insulin-like growth factor-I treatment in two children with growth hormone gene deletions | |
Castillo et al. | Macrophage Therapy Activates Endogenous Muscle Stem Cells and Accelerates Muscle Regeneration | |
EP1738763A1 (en) | Use of complement inhibitory proteins to treat spinal cord injury | |
AU2020372405A1 (en) | Methods and compositions for treating endometriosis | |
CN115884783A (en) | Low dose pharmaceutical compositions of GHRH analogs and uses thereof | |
AU2005202872A1 (en) | Use of complement inhibitory proteins to treat spinal cord injury | |
JPH10114675A (en) | Remedy for endotoxin induced disease | |
CA2508691A1 (en) | Use of complement inhibitory proteins to treat spinal cord injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680022383.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2608271 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006243905 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006784414 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006243905 Country of ref document: AU Date of ref document: 20060512 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11920304 Country of ref document: US |